Merck & Co. (MRK)
(Delayed Data from NYSE)
$103.75 USD
-0.13 (-0.13%)
Updated Dec 8, 2023 04:00 PM ET
After-Market: $103.56 -0.19 (-0.18%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Merck (MRK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$126.20 | $135.00 | $115.00 | 21.49% |
Price Target
Based on short-term price targets offered by 20 analysts, the average price target for Merck comes to $126.20. The forecasts range from a low of $115.00 to a high of $135.00. The average price target represents an increase of 21.49% from the last closing price of $103.88.
Analyst Price Targets (20)
Broker Rating
Merck currently has an average brokerage recommendation (ABR) of 1.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on 20 recommendations.
Of the 20 recommendations deriving the current ABR, 16 are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown

Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 13 | 13 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.40 | 1.40 | 1.40 | 1.56 | 1.56 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/27/2023 | BMO Capital Markets | Evan Seigerman | Not Available | Strong Buy |
10/17/2023 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
10/6/2023 | Truist Securities | Robyn Karnauskas | Strong Buy | Strong Buy |
9/5/2023 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
8/1/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/24/2023 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
5/1/2023 | Atlantic Equities | Steven K Chesney | Strong Buy | Strong Buy |
4/10/2023 | Mizuho SecuritiesUSA | Mara Goldstein | Strong Buy | Strong Buy |
1/30/2023 | Berenberg Bank | Luisa Hector | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.40 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 20 |
Average Target Price | $126.20 |
LT Growth Rate | 8.60% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 51 of 252 |
Current Quarter EPS Est: | 0.15 |